Archives

by in
Entry Author Date Location
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
Ex-Elan Trio Grabs Their Former Employer’s Kinase Inhibitor Program 09/29/14 San Francisco
East Coast Biotech Roundup: GliaCure, Civitas, T2, & More 09/29/14 Boston
PPD Acquires Drug Discovery Startup X-Chem 09/26/14 Raleigh Durham
Blessed By Angels, GliaCure Tests New Alzheimer’s Approach In Humans 09/26/14 Boston
Alkermes Spinoff Civitas, Poised for IPO, Sells to Acorda for $525M 09/24/14 Boston
Merrimack, Baxter Ink $970M+ Deal for Pancreatic Cancer Drug 09/24/14 Boston
With FDA Nod, T2 Bio’s Sepsis Test Heads to Commercial Proving Ground 09/23/14 Boston
“100K” Marathon: A Decades-Long Health Study Makes Its Business Case 09/23/14 National
Forum Highlights Innovators Working in Global Public Interest 09/19/14 San Francisco
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
Tokai Bags $97M For Prostate Cancer Drug in Upsized IPO 09/17/14 Boston
MyoKardia, Sanofi Ink $200M+ Deal for Targeted Heart Drugs 09/17/14 San Francisco
Proteon, Moving on From Ill-Fated Novartis Deal, Files IPO Pitch 09/16/14 Boston
East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More 09/15/14 Boston
Scholar Rock’s Local Approach to Immune Disease Nabs $20M 09/15/14 Boston
Hear Epizyme, Sage, Zafgen Share Their Stories on Oct. 8 09/11/14 Boston
Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships 09/10/14 Raleigh Durham
An Intriguing Program Takes on Tropical Diseases—But Not Ebola 09/10/14 National
To Fight Cramps, Christoph Westphal Taps Boston All-Stars for $40M 09/09/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
East Coast Biotech Roundup: Infinity, Merck, Voyager, Ebola, & More 09/05/14 Boston
Merck, Leapfrogging Bristol-Myers, Wins FDA Nod for Cancer Drug 09/04/14 New York
Google’s Calico Nabs First Partner, Cuts $1.5B R&D Deal With AbbVie 09/03/14 San Francisco
Steven Paul, Former Lilly R&D Chief, Takes Head Seat at Voyager 09/03/14 Boston
AbbVie Plunks Down $275M Upfront for Infinity’s Blood Cancer Drug 09/03/14 Boston
Exelixis Axes 70% of Workforce as Cancer Drug Flops, Shares Routed 09/02/14 San Francisco
ARCH Venture Exploits IPO Window To Raise $400M Fund, Its Eighth 08/27/14 Seattle
Coelacanths And Other IPO Thoughts Before The Autumn Markets Return 08/26/14 National
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? 08/25/14 San Francisco
Page 1 of 86 next page »